Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2Unknown 1Recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Head & Neck 2Genitourinary 2Tumor-Agnostic 1Sarcoma 1Other 1Gastrointestinal 1Endocrine 1Dermatologic 1Breast 1

Conditions

Thyroid Cancer, Papillary 1Leukoplakia, Oral 1Carcinoma, Renal Cell 1Adenocarcinoma, Follicular 1

Interventions

Cisplatin 263Radiotherapy 166Cetuximab 159Docetaxel 105Fluorouracil 104pembrolizumab 94Radiotherapy, Intensity-Modulated 83Carboplatin 80Paclitaxel 73Nivolumab 59Erlotinib Hydrochloride 35Surveys and Questionnaires 32Gemcitabine 32durvalumab 30Radiation 29Drug Therapy 25Immunohistochemistry 21Gefitinib 21Capecitabine 21tremelimumab 18Bevacizumab 18Surgical Procedures, Operative 17Sorafenib 17Magnetic Resonance Spectroscopy 17Ipilimumab 17Pemetrexed 16lenvatinib 15atezolizumab 15Radiosurgery 15Gene Expression Profiling 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Rosiglitazone × Head & Neck × Clear all
NCT01100619 2013-09-19

A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors

Exelixis

Phase 1 Completed
40 enrolled
EndocrineGenitourinaryHead & Neck

Thyroid Cancer, Papillary, Carcinoma, Renal Cell, Adenocarcinoma, Follicular

NCT00369174 2013-02-13

Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia

National Cancer Institute (NCI)

Phase 2 Completed
25 enrolled
Head & Neck

Leukoplakia, Oral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡